Rights issue 2022

This is Eevia

Eevia addresses global health challenges with bioactive extracts from natural, plant-based raw materials, that have clinically documented health benefits. Standardized plant extracts, with well-researched positive effects for human health, are sold B2B as ingredients to supplements, food, and cosmetic brands globally.

Founded in 2017, Eevia’s sales have grown with an average Q-on-Q growth of 25 percent to EUR 6.7m in total for the full year of 2021. Growth has continued in 2022 and the sales of the first half-year amounted to EUR 3.5m. Eevia operates a distributor business model in three continents and with indirect customers in 16 countries.

The Company has established the following financial targets for 2024 based on identified consumer demand and the production capacity, which the ongoing share issue enables;

  • Net sales above SEK 250 million
  • Gross margin above 40 %
  • EBITDA-margin above 15 %


Invitation to subscribe for shares in Eevia Health Plc 

Invitation to subscribe for shares in Eevia Health

Subscription of shares:
Subscription form (PDF)
Digital subscription (Bank-ID)


Price per share
SEK 1,50

SEK 21,6m

Subscription commitments

Subscription period
Nov 1st – 15th 2022

Trading in Subscription Rights
Nov 1st – 10th 2022